ICON reports second quarter 2021 financial results
Quarter 2 reported revenue of $871.2 million representing a year on year increase of 40.5% and 1.5% increase on Quarter 1 2021.
ICON acquisition creates world-leading healthcare intelligence and clinical research organisation
The combined company will leverage its enhanced operations to transform clinical trials and accelerate biopharma customer’s commercial success through the development of medicines and medical devices.
ICON shareholders vote in favour of all resolutions at its Extraordinary General Meeting
All resolutions at the ICON Extraordinary General Meeting held on June 15, 2021 (which resolutions had all been recommended by the Board) were all duly passed by shareholders.
ICON plc to Present at the Jefferies Virtual Healthcare Conference and the William Blair 41st Growth Stock Conference
The William Blair 41st Growth Stock Conference on Wednesday, June 2, 2021.
ICON plc to Present at the BofA Securities 2021 Virtual Healthcare Conference
The BofA Securities 2021 Virtual Healthcare Conference on Wednesday, May 12, 2021. The presentation will be webcast live from 08.00am ET.
ICON Reports First Quarter 2021 Results
Record net business wins in the quarter of $1,100 million, an increase of 27% year on year; a net book to bill of 1.28.
ICON wins multiple categories in 2021 CRO Leadership Awards for the fourth year in a row
ICON received 2021 CRO Leadership Awards. ICON achieved awards in both the Big Pharma and Overall groups.
Barclays Global Healthcare Conference
ICON plc to Present at the Barclays Global Healthcare Conference and the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum
ICON Reports Fourth Quarter and Full Year 2020 Results
Record net business wins in the quarter of $1,080 million; a book to bill of 1.42. Full year net business wins of $3.8 billion; a net book to bill of 1.38.
ICON to acquire PRA Health Sciences
Creating a world leader in Healthcare Intelligence and Clinical Research.